Xterna is an engineering biology firm that develops molecular binders capable of selectively targeting specific cell types for precise medication delivery. This technology addresses the challenge of effectively delivering therapeutics to the right cells, enhancing treatment efficacy for previously untreatable conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Effective drug delivery to specific cell types remains a significant challenge, limiting the efficacy of treatments and hindering the development of therapies for previously untreatable conditions. Traditional methods often lack precision, leading to off-target effects and reduced therapeutic impact.
Solution
Xterna engineers molecular binders that selectively target specific cell types, enabling precise drug delivery. This targeted approach enhances treatment efficacy by ensuring therapeutics reach the intended cells while minimizing exposure to healthy tissues. By improving the accuracy of drug delivery, Xterna's technology aims to unlock new possibilities for treating previously intractable diseases and improving patient outcomes.
Target Audience
Xterna's primary customers are pharmaceutical companies and research institutions developing targeted therapies for a range of diseases.
Features
- Engineered molecular binders with high specificity for target cell surface markers
- Customizable binder design to accommodate various therapeutic payloads
- Enhanced drug delivery precision, minimizing off-target effects
- Potential for improved treatment efficacy and reduced toxicity